These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 20485708)

  • 1. Aspirin, flu and general practice research.
    Parsons J
    Aust Fam Physician; 2010 May; 39(5):263. PubMed ID: 20485708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recruiting general practice patients for large clinical trials: lessons from the Aspirin in Reducing Events in the Elderly (ASPREE) study.
    Lockery JE; Collyer TA; Abhayaratna WP; Fitzgerald SM; McNeil JJ; Nelson MR; Orchard SG; Reid C; Stocks NP; Trevaks RE; Woods R
    Med J Aust; 2019 Mar; 210(4):168-173. PubMed ID: 30835844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin: promise and resistance in the new millennium.
    Patrono C; Rocca B
    Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):s25-32. PubMed ID: 18174450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancing the science of aspirin in primary prevention of vascular events.
    Cardiovasc J Afr; 2007; 18(5):347-8. PubMed ID: 17985039
    [No Abstract]   [Full Text] [Related]  

  • 6. Research in general practice in New Zealand.
    Reid J
    N Z Med J; 2003 Nov; 116(1186):U679. PubMed ID: 14657962
    [No Abstract]   [Full Text] [Related]  

  • 7. [The Primary Prevention Project Study Group. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice].
    De Caterina R
    Ital Heart J Suppl; 2001 Jun; 2(6):681-4. PubMed ID: 11460845
    [No Abstract]   [Full Text] [Related]  

  • 8. Should patients who have not had a cardiac event take ASA to prevent one?
    Alkhenizan A
    Can Fam Physician; 2002 Jan; 48():55-7. PubMed ID: 11852612
    [No Abstract]   [Full Text] [Related]  

  • 9. Aspirin for primary prevention of cardiovascular disease?
    Drug Ther Bull; 2009 Nov; 47(11):122-5. PubMed ID: 19887685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions.
    Hennekens CH; Sechenova O; Hollar D; Serebruany VL
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):170-6. PubMed ID: 17056829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin in the primary prevention of cardiovascular disease.
    Hennekens CH; Buring JE
    Cardiol Clin; 1994 Aug; 12(3):443-50. PubMed ID: 7805078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study protocol for a randomized controlled trial: the feasibility and impact of cardiovascular absolute risk assessment in Australian general practice.
    Wan Q; Harris MF; Zwar N; Campbell T; Patel A; Vagholkar S; McKenzie S; Walker C; Denney-Wilson E;
    Am Heart J; 2009 Mar; 157(3):436-41. PubMed ID: 19249412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis.
    Berger JS; Brown DL; Becker RC
    Am J Med; 2008 Jan; 121(1):43-9. PubMed ID: 18187072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on aspirin in the primary prevention of cardiovascular disease.
    Eidelman RS; Hebert PR; Weisman SM; Hennekens CH
    Arch Intern Med; 2003 Sep; 163(17):2006-10. PubMed ID: 14504112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis.
    Hennekens CH; Hollar D; Baigent C
    Nat Clin Pract Cardiovasc Med; 2006 Jan; 3(1):4-5. PubMed ID: 16391594
    [No Abstract]   [Full Text] [Related]  

  • 18. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Who needs antiplatelet therapy?
    Moher M; Lancaster T
    Br J Gen Pract; 1996 Jun; 46(407):367-70. PubMed ID: 8983259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. General practice research - training and capacity building.
    Magin P; Pirotta M; Farrell E; Van Driel M
    Aust Fam Physician; 2010 May; 39(5):265-6. PubMed ID: 20485709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.